10-Q: Supernus Reports Q3 Loss Amid Sage Acquisition, ONAPGO Launch

Supernus Pharmaceuticals reported a significant net loss in Q3 2025, driven by the Sage Therapeutics acquisition and increased expenses, despite strong sales growth for Qelbree and the launch of ONAPGO.

Summary

• Supernus Pharmaceuticals reported a net loss of $45.1 million for the three months ended September 30, 2025, compared to net earnings of $38.5 million in the same period of 2024.
• Diluted earnings per share (EPS) for Q3 2025 was a loss of $0.80, a significant decrease from $0.69 earnings per share in Q3 2024.
• Total revenues increased by 9% to $192.1 million in Q3 2025, up from $175.7 million in Q3 2024.
• Net product sales slightly decreased by 1% to $168.5 million in Q3 2025, primarily due to generic erosion of older products.
• Qelbree net sales grew by 31% to $81.4 million, and GOCOVRI net sales increased by 15% to $40.8 million in Q3 2025.
• ONAPGO, launched in April 2025, generated $6.8 million in net product sales in its first full quarter.
• Collaboration revenue from ZURZUVAE, acquired through the Sage acquisition, was $20.2 million for approximately two months of activity in Q3 2025.
• Selling, General and Administrative (SG&A) expenses surged by 158% to $179.7 million in Q3 2025, largely due to $8.6 million in transaction costs and $22.9 million in share-based compensation related to the Sage acquisition.
• The acquisition of Sage Therapeutics, Inc. was completed on July 31, 2025, for approximately $561 million in cash and up to $234 million in contingent value rights (CVRs).
• The FDA withdrew the New Drug Application (NDA) for OSMOLEX ER in September 2025.
• The Phase 2b study for SPN-820 in treatment-resistant depression (TRD) did not demonstrate a statistically significant improvement on primary and secondary endpoints.
• Supplier constraints are impacting the company's ability to fully meet demand for ONAPGO, leading to a pause in new patient initiations.
• The company was released from its Corporate Integrity Agreement (CIA) obligations in April 2025.

Sentiment

Score: 4

Explanation: The significant net loss and negative EPS, driven by acquisition costs and R&D setbacks, outweigh the positive sales growth of key products and the successful launch of ONAPGO. Supply constraints for ONAPGO and ongoing legal challenges add to the negative sentiment, despite the strategic acquisition of ZURZUVAE and its international approvals.

Positives

• Total revenues increased by 9% to $192.1 million in Q3 2025 compared to Q3 2024.
• Qelbree net sales grew by 31% to $81.4 million in Q3 2025, with total IQVIA prescriptions increasing by 23% year-over-year.
• GOCOVRI net sales increased by 15% to $40.8 million in Q3 2025, driven by growth in prescriptions and prescribers.
• ONAPGO, a new product launched in April 2025, generated $6.8 million in net product sales in its first full quarter.
• ZURZUVAE, acquired through the Sage acquisition, contributed $20.2 million in collaboration revenue in Q3 2025, with Biogen reporting a 150% increase in U.S. sales year-over-year.
• ZURZUVAE received approval for the treatment of PPD by the European Medicines Agency (EMA) and Medicines Healthcare Regulatory Agency (MHRA) in Europe and the U.K. respectively.
• The company was officially released from its Corporate Integrity Agreement (CIA) obligations in April 2025.
• Cash and cash equivalents increased by 118% to $151.4 million as of September 30, 2025, compared to December 31, 2024.

Negatives

• Reported a net loss of $45.1 million for Q3 2025, a significant decline from net earnings of $38.5 million in Q3 2024.
• Diluted EPS was a loss of $0.80 in Q3 2025, down from $0.69 earnings in Q3 2024.
• Operating earnings shifted to a loss of $60.2 million in Q3 2025 from a gain of $40.8 million in Q3 2024.
• Net product sales decreased by 1% in Q3 2025, primarily due to significant declines in older products.
• APOKYN net sales decreased by 48% to $10.4 million in Q3 2025.
• Trokendi XR net sales decreased by 34% to $10.0 million in Q3 2025 due to generic erosion.
• Oxtellar XR net sales decreased by 60% to $12.0 million in Q3 2025 due to generic erosion.
• Selling, General and Administrative (SG&A) expenses increased by 158% in Q3 2025, largely due to acquisition-related costs and accelerated share-based compensation from the Sage acquisition.
• The Phase 2b study of SPN-820 for treatment-resistant depression (TRD) did not meet its primary and secondary endpoints.
• Supplier constraints for ONAPGO are impacting the company's ability to meet demand, leading to a pause in new patient initiations.
• The FDA withdrew the New Drug Application (NDA) for OSMOLEX ER in September 2025.

Risks

• Generic competition for key products like Trokendi XR and Oxtellar XR is causing significant sales declines, and XADAGO faces forthcoming loss of exclusivity.
• Supplier constraints for ONAPGO are impacting the ability to meet demand, potentially leading to lost sales and requiring regulatory approval for new suppliers.
• Ongoing legal actions and proceedings, including patent infringement lawsuits for Qelbree, antitrust litigation for APOKYN, and various lawsuits related to the Sage acquisition (securities class action, SEC investigation, derivative litigations, merger complaints), could result in substantial costs, large judgments, and divert management attention.
• The commercialization efforts for ZURZUVAE may not be successful, or the product may not achieve broad market acceptance due to concerns about safety, tolerability, use while breastfeeding, or payor restrictions.
• The number of women with PPD and the potential market for ZURZUVAE may be smaller than expected.
• Future business prospects for ZURZUVAE currently depend on the company's ability, along with its collaboration partner, Biogen, to successfully continue to commercialize ZURZUVAE in the U.S. for the treatment of women with PPD.
• The company relies on single-source suppliers to produce and package final dosage forms for most commercial products and raw materials, including API, which could cause delays and loss of sales if a supplier change is needed.
• Tariffs imposed by the U.S. and other countries may increase costs for imported products and raw materials.
• Recent U.S. Executive Orders aiming to lower pharmaceutical product prices could negatively impact financial results.
• The company's estimates for fair values of acquired assets and liabilities, including contingent consideration, are inherently uncertain and subject to refinement, which could materially affect financial statements.

Future Outlook

The company plans to initiate a follow-on Phase 2b multi-center, randomized, double-blind, placebo-controlled trial for SPN-820 in approximately 200 adults with major depressive disorder (MDD) by the end of 2025, utilizing intermittent dosing. A Phase 1 single-ascending/multiple ascending dose study for SPN-443 in adult healthy volunteers for ADHD is expected to initiate in 2026. The company anticipates significant year-to-year variability in profits particularly due to continued market and payor pressures for commercial products, the unfavorable impact of the loss of patent exclusivity for Trokendi XR and Oxtellar XR, the potential unfavorable impact of the forthcoming loss of exclusivity of XADAGO, funding for research and development of product candidates, and additional funding for the launch of ONAPGO and marketing of ZURZUVAE. The company will continue to actively manage its capital structure and consider all financing opportunities that could strengthen its long-term financial profile.

Management Comments

• "We believe its balances of cash, cash equivalents, and unrestricted marketable securities, which totaled $281.2 million as of September 30, 2025, along with cash generated from ongoing operations and continued access to debt markets, will be sufficient to satisfy its cash requirements over the next 12 months and beyond."
• "While we expect continued profitability in future years, we anticipate there may be significant variability from year to year in the level of our profits particularly due to continued market and payor pressures for our commercial products; the unfavorable impact of the loss of patent exclusivity for Trokendi XR in January 2023 and Oxtellar XR in September 2024; the potential unfavorable impact of the forthcoming loss of exclusivity of XADAGO; funding for research and development of our product candidates; the additional funding for the launch of ONAPGO, which was approved by the FDA in February 2025 and launched in April 2025, and the additional funding for the marketing of ZURZUVAE which was acquired as part of the Sage Acquisition in July 2025."
• "We may, from time to time, consider raising additional capital through: new collaborative arrangements; strategic alliances; additional equity and/or financings from debt or other sources, especially in conjunction with opportunistic business development initiatives."
• "There can be no assurance that any such financing opportunities will be available on acceptable terms, if at all."

Industry Context

The biopharmaceutical industry, particularly in CNS diseases, is characterized by high R&D costs, intense competition, and the constant threat of generic erosion for established products. Supernus's strategy of acquiring new commercial products like ZURZUVAE and launching novel treatments like ONAPGO aims to offset revenue declines from older drugs facing generic competition (Trokendi XR, Oxtellar XR). The failure of SPN-820's Phase 2b trial for TRD highlights the inherent risks in drug development, while the quick pivot to an adjunctive MDD trial with intermittent dosing reflects adaptive R&D strategies. The supply constraints for ONAPGO underscore the fragility of global supply chains in the pharmaceutical sector. The ongoing legal battles against generic manufacturers are a standard industry practice to protect intellectual property and extend market exclusivity.

Corporate Governance

Legal Proceedings

• Multiple Qelbree patent infringement lawsuits filed against generic drug makers (Appco Pharma, Somerset Therapeutics, Apotex Inc., Aurobindo Pharma, Zydus Lifesciences, Creekwood Pharmaceuticals, MSN Pharmaceuticals, Zenara Pharma, Macleods Pharmaceuticals) to prevent generic versions from entering the market before patent expiration. Automatic stay prevents FDA approval until October 2, 2028.
• NAMENDA XR/Namzaric Qui Tam Litigation: Ninth Circuit affirmed dismissal of the Federal False Claims Act claim on January 29, 2025. Plaintiff's petition for rehearing denied, and no review sought from the U.S. Supreme Court. State-law FCA claims may be refiled.
• APOKYN Antitrust Litigation: Lawsuit alleging state and federal antitrust violations. Motions to dismiss were largely denied, and a jury trial is scheduled to begin on January 5, 2026. Mediation in April 2025 did not result in settlement. Discovery deadlines are currently suspended.
• US WorldMeds Partners, LLC v. Supernus Pharmaceuticals, Inc.: Lawsuit filed by Partners seeking payment of $27.7 million withheld from a $30.0 million ONAPGO milestone payment. Summary judgment motions are pending.
• Sage Legal Proceedings (post-acquisition): Includes Merger Complaints, a federal Securities Class Action, an SEC investigation related to zuranolone's NDA for MDD, and Consolidated Derivative Litigations. The outcomes are uncertain, and there is a potential for substantial costs or damages.
• US WorldMeds Partners, LLC v. Federal Insurance Company, et al.: Consolidated declaratory judgment actions seeking recovery of insurance benefits related to the APOKYN antitrust litigation. In early stages, discovery has not commenced.
• Supernus Pharmaceuticals, Inc. v. Old Republic Insurance Company: Action seeking recovery of insurance benefits related to the APOKYN antitrust litigation. Defendant's motion to dismiss is pending.

Related Party Transactions

• The company has a collaboration agreement with Biogen MA Inc. and Biogen International GmbH (Biogen) for the co-commercialization of ZURZUVAE in the U.S. The company reports collaboration revenue as 50% of total net revenue recorded by Biogen for ZURZUVAE in the U.S. and shares equally in costs for development and commercialization.

Stakeholder Impact

• Shareholders: Significant net loss and negative EPS may negatively impact investor confidence and share price. The Sage acquisition introduces new revenue streams (ZURZUVAE) but also substantial integration costs and legal liabilities. Generic erosion of older products continues to be a headwind.
• Customers (Patients/Prescribers): New product launches like ONAPGO and ZURZUVAE offer new treatment options for Parkinson's disease and postpartum depression. However, ONAPGO supply constraints may limit access for new patients. Expanded label for Qelbree provides more data for prescribers.
• Employees: The Sage acquisition involved accelerated vesting of Sage equity awards, resulting in significant compensation expense. Post-combination employee-related expenses also increased. The company's R&D pipeline continues to offer future development opportunities.
• Suppliers: Reliance on single-source suppliers for most commercial products, including ONAPGO, creates supply chain risk. Supplier constraints for ONAPGO are a current issue.
• Creditors: The company believes its cash and marketable securities, along with cash from operations and access to debt markets, will be sufficient to meet cash requirements. However, the decline in marketable securities due to the Sage acquisition and potential future capital raises could be relevant.

Next Steps

• Initiate a follow-on Phase 2b multi-center, randomized, double-blind, placebo-controlled trial for SPN-820 in approximately 200 adults with major depressive disorder (MDD) by the end of 2025, using intermittent dosing.
• Initiate a Phase 1 single-ascending/multiple ascending dose study for SPN-443 in adult healthy volunteers for ADHD in 2026.
• Work to build adequate inventory and resume new patient initiation for ONAPGO as soon as possible, providing timely updates on progress.
• Continue to defend against multiple Qelbree patent infringement lawsuits, with automatic stays preventing generic FDA approval until October 2, 2028.
• Continue to defend against the APOKYN antitrust litigation, with a jury trial scheduled for January 5, 2026.
• Await ruling on summary judgment motions in the US WorldMeds Partners, LLC v. Supernus dispute over a withheld milestone payment.
• Monitor and defend against ongoing legal proceedings related to the Sage acquisition, including a securities class action, SEC investigation, and derivative litigations.
• Finalize the purchase price allocation for the Sage acquisition within one year of the Sage Closing Date (July 31, 2025).

Key Dates

Recommendation

The company reported a significant net loss for the quarter and year-to-date, primarily driven by substantial acquisition-related costs from the Sage Therapeutics acquisition and increased SG&A expenses. While the acquisition of ZURZUVAE and the launch of ONAPGO represent strategic growth initiatives and show promising early sales, these positives are currently overshadowed by the financial impact of the acquisition, R&D setbacks (SPN-820 Phase 2b failure), and ongoing generic erosion of older products. The ONAPGO supply constraint is also a concern. The extensive legal proceedings, including patent infringement and antitrust lawsuits, introduce considerable uncertainty and potential future liabilities. Given the mixed financial performance, strategic investments, and significant operational and legal risks, a 'hold' recommendation is appropriate. Investors should monitor the successful integration and commercialization of ZURZUVAE, resolution of ONAPGO supply issues, progress in the R&D pipeline, and outcomes of the various legal challenges before considering a stronger position.

Keywords

Supernus Pharmaceuticals, SUPN, 10-Q, Quarterly Report, Biopharmaceutical, CNS diseases, Qelbree, ADHD, GOCOVRI, Parkinson's Disease, ONAPGO, ZURZUVAE, Postpartum Depression, PPD, Sage Acquisition, Net Loss, Generic Competition, Patent Litigation, SPN-820, Clinical Trials, Supply Chain, SEC Investigation, Antitrust Litigation